期刊文献+

胰岛素泵治疗老年2型糖尿病的临床观察 被引量:8

Clinical Study on Insulin Pump for Elderly Patients with Type 2 Diabetes
原文传递
导出
摘要 目的观察短期胰岛素泵持续皮下输注(CSII)门冬胰岛素与预混人胰岛素30R常规2次皮下注射对老年2型糖尿病患者的疗效差异。方法将50例2型糖尿病患者随机分为两组,其中A组采用CSII治疗,持续皮下输注门冬胰岛素,B组于早、晚餐前30min注射预混人胰岛素30R,比较治疗后两组空腹血糖、餐后血糖、血糖达标时间、胰岛素用量、低血糖发生率。结果CSII组和预混人胰岛素30R常规2次皮下注射组均可有效降低血糖(P<0.01),治疗后A、B组空腹血糖比较差异无统计学意义(P>0.05),但餐后2h血糖A组控制优于B组(P<0.05)。CSII组低血糖发生率明显低于预混人胰岛素30R常规2次皮下注射组(P<0.05),尤其是夜间严重低血糖事件的发生率明显降低。结论在老年2型糖尿病患者中短期应用胰岛素泵输注门冬胰岛素降糖效果显著,安全性高,患者耐受性和依从性好。 Objective To observe the clinical effect and safety between continuous subcutaneous insulin infusion(CSII) of insulin aspart and Novolin 30R in treating elderly patients with type 2 diabetes mellitus. Methods 50 patients with type 2 DM were randomly divided into A group and B group, Novolin 30R was used in B group and was treated twice daily in morning and evening. CSII of insulin aspart was used in A group( DANA Diabecare). Drug dose was adjusted according to the level of blood glucose. The levels of fasting plasma glucose (FPG) ,2 hours postprandial glucose( 2 h PG), therapeutic time, insulin dose and the incidence of hypoglycemia were compared between the two groups. Results CSII group and Novolin 30R group could decrease blood glucose efficiently( P 〈 0.01 ), the levels of fasting plasma glucose(FPG) was no significant differences in the two groups (P 〉 0.05 ), but 2 hours postprandial glucose(2 h PG) in CSII group was lower than Novolin 30R group (P 〈 0. 05 ). The incidence of hypoglycemia in the CSII group was more lower than the Novolin 30R group( P 〈0.05 ) and especially the incidence of severe hypoglycemia at night. Conclusion Continuous subcutaneous insulin infusion of insulin aspart is an effective and high safety in the treatment of type 2 diabetes mellitus in elderly patients.
出处 《中华全科医学》 2009年第3期256-256,275,共2页 Chinese Journal of General Practice
关键词 2型糖尿病 胰岛素泵 门冬胰岛素 预混人胰岛素 Type 2 diabetes Insulin pump Insulin aspart Novolin 30R
  • 相关文献

参考文献7

二级参考文献11

  • 1王先令,陆菊明.血糖波动对糖尿病预后及其慢性并发症发生发展的影响[J].国外医学(内分泌学分册),2005,25(3):169-171. 被引量:135
  • 2Juhl CB, Porksen N, Hollingdal M, et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequencv. Diabetes Care 2000; 23: 675 - 81.
  • 3Weyer C. Bpgardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
  • 4Hollingdal M, Juhl CB, Pincus SM, et al. Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes 2000 ;49:1334 - 40.
  • 5Kahn SE. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab2001 ;86: 4047 - 58.
  • 6Brownlee MA. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2004; 53 (Suppl 2): 6.
  • 7Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26: 2231 - 37.
  • 8Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353 - 6.
  • 9Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.Diabetes 2002;51:2796-803.
  • 10Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabetes Care2004 ;27: 2585 - 89.

共引文献265

同被引文献40

引证文献8

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部